Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

BACKGROUND: In a phase 1 dose-escalation study, combined inhibition of T-cell checkpoint pathways by nivolumab and ipilimumab demonstrated a high objective response rate, including complete responses in patients with advanced melanoma. METHODS: In this double-blind study, 142 treatment-naïve patient...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:N Engl J Med
Asıl Yazarlar: Postow, Michael A., Chesney, Jason, Pavlick, Anna C., Robert, Caroline, Grossmann, Kenneth, McDermott, David, Linette, Gerald P., Meyer, Nicolas, Giguere, Jeffrey K., Agarwala, Sanjiv S., Shaheen, Montaser, Ernstoff, Marc S., Minor, David, Salama, April K., Taylor, Matthew, Ott, Patrick A., Rollin, Linda M., Horak, Christine, Gagnier, Paul, Wolchok, Jedd D., Hodi, F. Stephen
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2015
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5744258/
https://ncbi.nlm.nih.gov/pubmed/25891304
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1414428
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller